Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Cyclophosphamide for Refractory CIDP
NCT01236456Phase 2Withdrawn
- Sponsor
- Stony Brook University
- Start
- Oct 2003
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Stony Brook University. Primary endpoint: Response Rate. Planned start Oct 2003; status: withdrawn.
02
Drugs
cyclophosphamide
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT01236456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01236456.